Omalizumab + Omalizumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cold Contact Urticaria
Conditions
Cold Contact Urticaria
Trial Timeline
Apr 1, 2012 → Feb 1, 2015
NCT ID
NCT01580592About Omalizumab + Omalizumab + Placebo
Omalizumab + Omalizumab + Placebo is a phase 2 stage product being developed by Novartis for Cold Contact Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT01580592. Target conditions include Cold Contact Urticaria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02169115 | Phase 2 | Completed |
| NCT01580592 | Phase 2 | Completed |
Competing Products
20 competing products in Cold Contact Urticaria